CN113226286B - 1,2-二氢吡啶化合物的水基药物制剂 - Google Patents
1,2-二氢吡啶化合物的水基药物制剂 Download PDFInfo
- Publication number
- CN113226286B CN113226286B CN201980081856.7A CN201980081856A CN113226286B CN 113226286 B CN113226286 B CN 113226286B CN 201980081856 A CN201980081856 A CN 201980081856A CN 113226286 B CN113226286 B CN 113226286B
- Authority
- CN
- China
- Prior art keywords
- perampanel
- cyclodextrin
- pharmaceutical formulation
- sulfobutyl ether
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862779620P | 2018-12-14 | 2018-12-14 | |
| US62/779,620 | 2018-12-14 | ||
| PCT/US2019/066622 WO2020124090A1 (en) | 2018-12-14 | 2019-12-16 | Aqueous based pharmaceutical formulations of 1,2-dihydropyridine compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113226286A CN113226286A (zh) | 2021-08-06 |
| CN113226286B true CN113226286B (zh) | 2024-08-20 |
Family
ID=69174604
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980081856.7A Active CN113226286B (zh) | 2018-12-14 | 2019-12-16 | 1,2-二氢吡啶化合物的水基药物制剂 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12303499B2 (https=) |
| EP (1) | EP3893844A1 (https=) |
| JP (1) | JP7177937B2 (https=) |
| KR (1) | KR102912861B1 (https=) |
| CN (1) | CN113226286B (https=) |
| AU (1) | AU2019395288B2 (https=) |
| BR (1) | BR112021010953A2 (https=) |
| CA (1) | CA3122705A1 (https=) |
| MA (1) | MA54460A (https=) |
| MX (1) | MX2021006317A (https=) |
| WO (1) | WO2020124090A1 (https=) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018169798A1 (en) * | 2017-03-11 | 2018-09-20 | The Regents Of The University Of California | Mitigation of cns disorders by combination therapy using neurosteroids, and ampa blockers |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5356902A (en) | 1992-11-06 | 1994-10-18 | Eli Lilly And Company | Decahydroisoquinoline compounds as excitatory amino acid receptor antagonists |
| IL109397A0 (en) | 1993-04-28 | 1994-07-31 | Schering Ag | Quinoxalinedione derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same |
| HU219777B (hu) | 1993-07-02 | 2001-07-30 | Gyógyszerkutató Intézet Kft. | Optikailag aktív 1-(4-nitro-fenil)-4-metil-7,8-metiléndioxi-3,4-dihidro-5H-2,3-benzodiazepin és eljárás előállítására |
| DK0784054T3 (da) | 1994-09-27 | 2002-03-25 | Yamanouchi Pharma Co Ltd | 1,2,3,4-tetrahydroquinoxalinderivater og deres anvendelse som glutamatreceptorantagonister |
| US5935551A (en) | 1995-11-15 | 1999-08-10 | California Institute Of Technology | Synthesis of zeolites by hydrothermal reaction of zeolite P1 |
| DE19604920A1 (de) | 1996-02-01 | 1997-08-07 | Schering Ag | Neue 2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel |
| US5891871A (en) | 1996-03-21 | 1999-04-06 | Cocensys, Inc. | Substituted 2,3-benzodiazepin-4-ones and the use thereof |
| HU9600871D0 (en) | 1996-04-04 | 1996-05-28 | Gyogyszerkutato Intezet | New 2,3-benzodiazepine derivatives |
| CN1103772C (zh) | 1996-05-15 | 2003-03-26 | 辉瑞大药厂 | 新的2,3－二取代－4(3h)－喹唑啉酮类化合物 |
| DE19643037A1 (de) | 1996-10-18 | 1998-04-23 | Boehringer Ingelheim Kg | Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel |
| SK113299A3 (en) | 1997-02-28 | 2001-05-10 | Pfizer Prod Inc | Atropisomers of 3-aryl-4(3h)-quinazolinones and their use as ampa-receptor antagonists |
| GB9711753D0 (en) | 1997-06-06 | 1997-08-06 | Merck Sharp & Dohme | Therapeutic agents |
| WO2000001376A2 (en) | 1998-07-02 | 2000-01-13 | Eisai Co., Ltd | Pharmaceutical compositions and their uses for treatment of demyelinating disorders |
| DE19835918A1 (de) | 1998-08-07 | 2000-02-10 | Dresden Arzneimittel | Neue antikonvulsiv wirkende 4-Amino-1-aryl-pyridin-2-one und Verfahren zu deren Herstellung |
| ES2320973T3 (es) | 2000-06-12 | 2009-06-01 | EISAI R&D MANAGEMENT CO., LTD. | Compuestos de 1,2-dihidropiridina, procedimiento para su preparacion y uso de los mismos. |
| GB0129260D0 (en) | 2001-12-06 | 2002-01-23 | Eisai London Res Lab Ltd | Pharmaceutical compositions and their uses |
| MY148809A (en) | 2004-07-06 | 2013-05-31 | Eisai R&D Man Co Ltd | Crystals of 1,2-dihydropyridine compound and their production process |
| US7803818B2 (en) | 2005-12-21 | 2010-09-28 | Eisai R&D Management Co., Ltd. | Amorphous form of 1,2-dihydropyridine compound |
| WO2008111590A2 (en) | 2007-03-05 | 2008-09-18 | Eisai R & D Management Co., Ltd. | Ampa and nmda receptor antagonists for neurodegenerative diseases |
| JP2015227288A (ja) * | 2012-08-31 | 2015-12-17 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | けいれん重積発作の治療用医薬組成物 |
| CN104644592A (zh) * | 2013-11-25 | 2015-05-27 | 天津市汉康医药生物技术有限公司 | 一种吡仑帕奈药物组合物及其制备方法 |
| CN104706604A (zh) * | 2013-12-12 | 2015-06-17 | 北京星昊医药股份有限公司 | 一种吡仑帕奈冻干口崩片及其制备方法 |
| CA2973140C (en) * | 2015-02-06 | 2025-09-16 | Marinus Pharmaceuticals, Inc. | Intravenous Ganaxolone Formulations and Their Use in the Treatment of Status Epilepticus and Other Epileptic Disorders |
| CN106389367B (zh) | 2016-11-16 | 2020-12-18 | 杭州朱养心药业有限公司 | 吡仑帕奈包衣片剂药物组合物 |
-
2019
- 2019-12-16 MA MA054460A patent/MA54460A/fr unknown
- 2019-12-16 KR KR1020217017514A patent/KR102912861B1/ko active Active
- 2019-12-16 CA CA3122705A patent/CA3122705A1/en active Pending
- 2019-12-16 WO PCT/US2019/066622 patent/WO2020124090A1/en not_active Ceased
- 2019-12-16 CN CN201980081856.7A patent/CN113226286B/zh active Active
- 2019-12-16 AU AU2019395288A patent/AU2019395288B2/en active Active
- 2019-12-16 JP JP2021530970A patent/JP7177937B2/ja active Active
- 2019-12-16 EP EP19839214.4A patent/EP3893844A1/en active Pending
- 2019-12-16 US US17/312,077 patent/US12303499B2/en active Active
- 2019-12-16 BR BR112021010953-6A patent/BR112021010953A2/pt unknown
- 2019-12-16 MX MX2021006317A patent/MX2021006317A/es unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018169798A1 (en) * | 2017-03-11 | 2018-09-20 | The Regents Of The University Of California | Mitigation of cns disorders by combination therapy using neurosteroids, and ampa blockers |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019395288A1 (en) | 2021-09-23 |
| WO2020124090A1 (en) | 2020-06-18 |
| AU2019395288B2 (en) | 2025-04-03 |
| US20220023275A1 (en) | 2022-01-27 |
| MA54460A (fr) | 2021-10-20 |
| US12303499B2 (en) | 2025-05-20 |
| KR20210107644A (ko) | 2021-09-01 |
| KR102912861B1 (ko) | 2026-01-15 |
| JP7177937B2 (ja) | 2022-11-24 |
| MX2021006317A (es) | 2021-08-11 |
| EP3893844A1 (en) | 2021-10-20 |
| JP2022510947A (ja) | 2022-01-28 |
| CN113226286A (zh) | 2021-08-06 |
| BR112021010953A2 (pt) | 2021-08-24 |
| CA3122705A1 (en) | 2020-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6106228B2 (ja) | 過増殖性疾患、自己免疫疾患、および心疾患の治療のための３−キヌクリジノンを含有する水溶液 | |
| CA3077489A1 (en) | Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections | |
| CA2943213C (en) | Aripiprazole formulations having increased injection speeds | |
| MX2011012640A (es) | Composiciones inyectables de melfalan que comprenden un derivado de ciclodextrina y metodos de fabricacion y uso de las mismas. | |
| WO2008148080A2 (en) | Pharmaceutical compositions of [5(s)-(2'-hydroxyethoxy)-20(s)-camptothecin] | |
| AU2022211854A1 (en) | Aqueous formulation comprising 1-(4-{(4-(dimethylamino)piperidin-1-yl)carbonyl}phenyl)-3-(4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl)urea | |
| CN102772409B (zh) | 一种药物组合物 | |
| CN109562073B (zh) | 白蛋白药物组合物及其制备方法 | |
| KR102416050B1 (ko) | 사이클로덱스트린-파노비노스타트 부가물 | |
| JP2016521732A (ja) | 安定な抗がん剤のアルギニン塩とそれを含む組成物 | |
| CN113226286B (zh) | 1,2-二氢吡啶化合物的水基药物制剂 | |
| AU2019373373A1 (en) | Cyclodextrin-based formulation of a Bcl-2 inhibitor | |
| RU2824582C2 (ru) | Водные фармацевтические составы на основе 1,2-дигидропиридиновых соединений | |
| CA3117511C (en) | Cyclodextrin-based formulation of a bcl-2 inhibitor | |
| Chavan et al. | Solid state characterization of multicomponent inclusion complex of domperidone with β-cyclodextrin, polyvinyl pyrrolidone and citric acid | |
| Couto | Association of capsaicin with local anesthetics to increase analgesia | |
| HK1236852A1 (en) | Aqueous solution comprising 3-quinuclidinone derivative for the treatment of hyperproliferative diseases, autoimmune diseases and heart diseases | |
| NZ723869B2 (en) | Aripiprazole formulations having increased injection speeds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |